Dosing
*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 8/21/23.
One migraine treatment in a 75 mg dose provides rapid relief or powerful prevention in your patients' hands1,2
ACUTE TREATMENT
One 75 mg ODT, as needed, for the acute treatment of migraine with or without aura.1
PREVENTIVE TREATMENT
One 75 mg ODT every other day for the preventive treatment of episodic migraine.1
24h
24-hour max:
one 75 mg ODT
- Nurtec ODT has a Tmax of 1.5 hours.1
- The half-life of Nurtec ODT is ~11 hours.1
- The safety of using more than 18 doses in a 30-day period has not been established.1
I take one dose of Nurtec ODT, it dissolves in seconds and gets me back to what I love.
Corinne S.
Actual Nurtec ODT patient.
Individual results may vary.
I am able to get quick pain relief and get back to normal function when a migraine attacks, in just one dose.
Alexandra N.
Actual Nurtec ODT patient.
Individual results may vary.
Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.
The only CGRP receptor antagonist available as an orally disintegrating tablet1,3
CGRP=calcitonin gene-related peptide.
*Store Nurtec ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F).1
†The safety of using more than 18 doses in a 30-day period has not been established.1
Instructing patients on how to take Nurtec ODT
References: 1. Nurtec ODT. Package insert. Pfizer Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi: 10.1016/S0140-6736(20)32544-7 3. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally dissolving tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi:10.1016/S0140-6736(19)31606-X 4. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 5. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Data on File. RIM130. Pfizer Inc. 7. Abay FB, Ugurlu T. Orally disintegrating tablets: a short review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303